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Stem cells are fundamental units for achieving regenerative therapies, which leads naturally to a theoretical
and experimental focus on these cells for therapeutic screening and intervention. A growing body of data in
many tissue systems indicates that stem cell function is critically influenced by extrinsic signals derived from
the microenvironment, or ‘‘niche.’’ In this vein, the stem cell niche represents a significant, and largely
untapped, entry point for therapeutic modulation of stem cell behavior. This Perspective will discuss how
the niche influences stem cells in homeostasis, in the progression of degenerative and malignant diseases,
and in therapeutic strategies for tissue repair.Effective functioning of the body’s tissues and organs depends
upon innate regenerative processes that maintain proper cell
numbers (homeostasis) and replace damaged cells after injury
(repair). In many though not all tissues, regenerative potential
is determined by the presence and functionality of a dedicated
population of stem and progenitor cells, which respond to exog-
enous cues to produce replacement cells when needed. Under-
standing how these unspecialized precursors aremaintained and
regulated is essential for understanding the fundamental biology
of tissues. This knowledge also has practical implications, as the
regenerative potential of tissue-specific stem and progenitor
cells can be exploited therapeutically by transplantation to
replenish the stem cell pool, by endogenous manipulation to
boost the repair activity of cells already present in the tissue, or
through in vitro modeling of development and disease to provide
otherwise inaccessible systems for identifying pathological
mechanisms and testing the efficacy of newly discovered drugs.
Indeed, the promise of stemcell biology for the development of
novel therapeutics has fueled a veritable explosion in studies
aimed at using these cells in ‘‘regenerative medicine,’’ an
emerging field of biomedicine focused on the ‘‘repair, replace-
ment, or regeneration of cells, tissues or organs’’ (Mason and
Dunnill, 2008). Yet such strategies ultimately must consider and
address biological constraints imposed by both the stem cell
itself and the environment, or niche, in which the stem cell is
asked to function. In this Perspective, I review existing and
emerging evidence suggesting that the stem cell niche repre-
sents a particularly attractive and relatively underexploited entry
point for the discovery of novel stem cell regulatory mechanisms
and the development of newapplications in regenerative biology.
Several new and exciting studies, in both the hematopoietic
(blood-forming) system and solid organs, have highlighted the
potential of such approaches. This work likely represents the
shallow end of a very deep pool, which upon further investigation
will yield new paradigms for understanding and controlling stem
cell functions to achieve therapeutically valuable results.
Stem Cells and Their Niches
As the functional units for growth and regeneration in many
tissues, stem cells hold a position of significant importance for362 Cell Stem Cell 10, April 6, 2012 ª2012 Elsevier Inc.maintaining proper tissue function. Thus, these cells should be
protected as much as possible from damage or loss, while at
the same time maintaining sufficient communication with their
surroundings to ensure appropriate responsiveness to physio-
logical cues for cell replacement and repair. In many tissues,
this balance between protection and interaction appears to be
accomplished by maintaining stem cells in a specialized micro-
environment, or niche, which provides spatial and temporal
cues to support and coordinate stem cell activities (Wang and
Wagers, 2011). Stem cell niches have been identified and char-
acterized in many tissues, including the germline, bone marrow,
digestive and respiratory systems, skeletal muscle, skin, hair
follicle, mammary gland, and central and peripheral nervous
systems. Extensive studies in a number of different laboratories
have begun to elucidate the critical components of many stem
cell niches, which include specific mesenchymal, vascular,
neuronal, glial, and inflammatory cell types, diffusible and cell-
surface-associated signaling molecules, and physical parame-
ters such as matrix rigidity, shear stress, oxygen tension, and
temperature (see Figure 1; reviewed in Bautch, 2011; Ehninger
and Trumpp, 2011; Jones and Wagers, 2008; Morrison and
Spradling, 2008; Peerani and Zandstra, 2010; Raaijmakers,
2011; Sneddon and Werb, 2007; Voog and Jones, 2010; Wang
and Wagers, 2011; Wilson and Trumpp, 2006). In particular,
cell-cell interactions within the niche provide structural support,
regulate adhesive interactions, and produce soluble signals that
can control stem cell function. Stem cell interactions with the
extracellular matrix (ECM) provide retention cues, as well as
mechanical signals, based in part on substrate rigidity (Engler
et al., 2006; Gilbert et al., 2010), which allow stem cells to
respond to external physical forces. In addition, the ECM can
sequester or concentrate growth factors, chemokines, and other
stem cell regulatory molecules by binding both locally and
systemically produced factors within the niche (Yamazaki
et al., 2011). The close association of many stem cell types
with the vasculature and nervous system allows for modulation
of stem cell responses by metabolic cues and circadian rhythms
(Kiel et al., 2005; Me´ndez-Ferrer et al., 2008, 2009, 2010), and
provides a conduit through which inflammatory and immune
cells, as well as humoral factors, can be delivered to the niche
Figure 1. Constituents of a Stem Cell Niche
Stem cell niches are highly complex and dynamic, including both cellular and acellular components. This schematic depicts many of the critical constituents of
stem cell niches, drawing predominantly from data in the hematopoietic system, and also including data from the skeletal muscle and gut. Labels are color-coded
to match objects in the diagram, and some examples are given where appropriate. Please see text for additional detail. ECM, extracellular matrix; GPCRs,
G protein-coupled receptors; MSC, mesenchymal stem cell.
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Trumpp, 2011). Finally, temperature, shear forces, and chemical
signals provided by the niche also influence stem cell behavior in
response to the external environment (Adams et al., 2006; North
et al., 2009; Wang and Wagers, 2011). Importantly, while the
specific components that constitute a particular stem cell niche
may vary in different tissues and under distinct physiological
contexts, in all cases the signals provided by these cellular and
acellular components appear to be integrated by stem cells to
inform their fate decisions, including choices between quies-
cence or proliferation, self-renewal or differentiation, migration
or retention, and cell death or survival.
The pivotal role of the niche in determining stem cell functions
presents a powerful opportunity to manipulate stem cells to
enhance their therapeutic efficacy. Indeed, because the niche,
by definition, impacts stem cell function extrinsically, it may be
argued that this anatomical structure represents an even more
‘‘druggable’’ target for regenerative medicine than the stem
cell itself. Such ‘‘niche therapies’’ could be applied to enhance
stem cell functionality—in transplantation, through endogenous
targeting, or via in vitro model systems (Figure 2). The following
paragraphs consider the progress, challenges, and opportuni-
ties for such approaches and how understanding the stem cell
niche may ultimately enable full realization of the promise each
presents.
Targeting the Niche to Enhance Stem Cell Transplant
for Regenerative Medicine
One of themost celebrated successes in the use of stem cells for
regenerative medicine has been the clinical implementation of
bonemarrow transplantation for regeneration of the blood-form-
ing system (Thomas, 2000). The process of bone marrow trans-
plant typically involves the harvesting of donor cells containing
hematopoietic stem cells (HSCs) from either the marrow cavity
or peripheral blood (after treatment with appropriate ‘‘mobi-
lizing’’ agents that induce themigration of HSCs from themarrow
into circulation), and infusion of those cells into a recipient whose
own blood-forming cells have been impaired or ablated bychemotherapy or radiation. Thus, a primary challenge in bone
marrow transplant (and likely in other tissue-specific transplant
approaches that may be pursued in future studies) is achieving
sufficient regeneration in a short enough period of time to be
effective. In the case of the blood system, this requires (1) collec-
tion of sufficient numbers of stem cells for transplant, (2) efficient
migration of these cells after intravenous injection to their proper
locations within the bone marrow, and (3) proliferation of these
cells in the body to rapidly replenish lost cells. Ineffectiveness
or inefficiency at any of these steps can result in life-threatening
graft failure. Therefore, strategies that can boost the rate or
extent of regeneration, either by providing more regenerative
cells or by increasing the per cell output of each stem cell trans-
ferred, may significantly reduce transplant-associated risk and
increase the rate of successful engraftment. Importantly, strate-
gies that target the stem cell niche could aid in both approaches.
Indeed, targeting of the stem cell niche is already effectively em-
ployed in the clinical practice of marrow transplantation, wherein
donors are treated with stem cell mobilizing agents, such as
granulocyte-colony stimulating factor (G-CSF) or AMD3100.
These agents activate niche remodeling and disrupt the normal
interactions of HSCs with the marrow environment (Broxmeyer
et al., 2005; Kollet et al., 2006; Me´ndez-Ferrer et al., 2010),
thereby causing the egress of stem cells into the peripheral
circulation where they can be easily collected for subsequent
transplantation. Likewise, administration of lineage-specific
hematopoietic cytokines, including granulocyte-macrophage-
colony stimulating factor (GM-CSF) or erythropoietin, is routinely
employed to support the enhanced production of particular
blood cell lineages in patients with deficiencies in leukocytes
or leukocyte subsets.
In addition to targeting the niche throughmobilizing and differ-
entiation agents, much interest has focused on strategies that
may recapitulate a stem cell expanding niche ex vivo. Such
approaches, if successful, could in theory generate increased
numbers of cells for transplant. Although such ex vivo expansion
approaches have been pursued formany decades, unfortunately
for the most part without significant gains (Dahlberg et al., 2011),Cell Stem Cell 10, April 6, 2012 ª2012 Elsevier Inc. 363
Figure 2. Potential Entry Points for Niche-Directed Stem Cell Therapies
Targeting the stem cell niche could have therapeutic value in a number of strategies aimed at using or manipulating stem cells for regenerative medicine. In the
context of transplantation, ex vivo recapitulation of niche-derived signals could be used to expand stem cells for subsequent transplant (A), or to expand or alter
the niches that are available in vivo in transplant recipients (B). Direct targeting of niche cells in vivo also could be used to replenish lost niches or reverse niche
dysfunction (C), thereby restoring or enhancing endogenous regenerative potential. Conversely, modified, tumor-supportive niches could be targeted for deletion
or modification to counteract their growth and metastasis-promoting activities (D). Finally, reconstitution of stem cell niches ex vivo has the potential to provide
necessary extrinsic cues, which are lacking in cultures containing stem cells alone (E), to initiate in culture normal processes of development (F) that typically are
inaccessible to experimental interrogation, and to uncover how these processesmay be perturbed in disease to impede or pervert normal stem cell differentiation
(G). Intervention in any of these culture systems with gene modification or small molecule supplementation could also provide novel systems for drug discovery.
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plexity of the stem cell niche coupled with improved technolo-
gies for high-throughput screening and biomaterials fabrication
are likely to reinvigorate this area of investigation (Peerani and
Zandstra, 2010). Previous studies have reported successful
expansion of clinically relevant numbers of hematopoietic
stem and progenitor cells through endogenous (Varnum-Finney
et al., 2000) or ligand-mediated (Varnum-Finney et al., 2003) acti-
vation of Notch signaling (a conserved cell-cell communication
pathway that regulates cell fate and differentiation events in
many different metazoan tissues; Liu et al., 2010). More recently,
work using microfabricated arrays of stem cell regulatory factors
(i.e., Wnt, Notch, and BMP2) together with ECM components
demonstrated a complex interplay between matrix proteins
and growth factors in the regulation of self-renewal and differen-
tiation of neural stem cells (Soen et al., 2006). Moreover, studies
of skeletal muscle stem cells have provided compelling data
indicating that even relatively simplistic interventions, such as364 Cell Stem Cell 10, April 6, 2012 ª2012 Elsevier Inc.modulation of substrate elasticity, can profoundly impact the
ex vivo expansion of regenerative cells, enabling significant
tissue engraftment to be obtained from as few as 10 cultured
precursor cells (Gilbert et al., 2010). Such modulation of matrix
rigidity also has been used to bias the differentiation potential
of mesenchymal stromal cells (MSCs), with stiffer matrices
favoring osteogenic lineages (Engler et al., 2006). It is likely
that similar principles, when applied to hematopoietic or other
tissue stem cell systems,may have equivalently useful outcomes
for stem cell expansion and cell fate modulation. Likewise, high
throughput chemical screening using purified human HSCs has
identified soluble signals, such as inhibition of ligand-induced
signaling by the aryl hydrocarbon receptor (AhR), that can
promote in vitro expansion of umbilical cord and mobilized
peripheral blood-derived human HSCs (Boitano et al., 2010;
M. Cooke, personal communication). Such unbiased screens
likely illuminate natural mechanisms used by niche cells in vivo
to modulate stem cell expansion, and thus, future studies of
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nous niche signals to prioritize candidate pathways.
Niche-directed interventions also might be employed to boost
support for transplanted stem cells after transplantation. In this
regard, compelling preclinical data in mice suggest that activa-
tion of osteolineage cells by parathyroid hormone (PTH), which
promotes the proliferation of nestin+ mesenchymal cells and
encourages osteolineage differentiation (Calvi et al., 2003; Me´n-
dez-Ferrer et al., 2010), speeds posttransplant recovery of
peripheral mature cells, improves pharmacological mobilization
of HSCs, and protects mice from otherwise lethal hematoabla-
tive chemotherapy (Adams et al., 2007). Such studies supported
the initiation of clinical trials to test the impact of PTH supple-
mentation on donor cell mobilization and engraftment during
sequential cord blood transplantation (ClinicalTrials.gov Identi-
fier numbers: NCT00393380 and NCT00299780). Although
the engraftment study was stopped early when toxicity
endpoints (thought to be transplant-related, rather than drug-
induced) were met, outcomes from the mobilization trial indi-
cated that about half of patients who had failed a previous round
of mobilization mobilized successfully after PTH (D. Scadden,
personal communication). In a similar approach, treatment of
irradiated mice with the peroxisome proliferator-activated
receptor-gamma (PPAR-g) inhibitor bisphenol A diglycidyl ether
accelerated hematopoietic engraftment, apparently via inhibition
of marrow adipogenesis (Naveiras et al., 2009). Such interven-
tions, which target mesenchymal cell types that are components
of the HSC niche in the bone marrow, may be particularly rele-
vant for improving transplantation outcomes in aged individuals,
who typically exhibit reduced bone density and increased
adiposity. These age-related microenvironmental alterations
could impair HSC function, and so, reversal of these changes
might be predicted to enhance therapeutic engraftment in
aged individuals (see below).
Targeting Endogenous Niches to Promote Regenerative
Activity or Impede Deregulated Growth
In many acute and degenerative diseases, alterations in the stem
cell niche may activate stem cell suppressive mechanisms that
impair tissue regenerative potential (for review, see Jones and
Rando, 2011; Liu and Rando, 2011; Rossi et al., 2008). This
phenomenon is particularly evident in the context of physiolog-
ical aging, where a number of tissues exhibit profound alter-
ations in stem cell number and activity that coincide with
reduced tissue function and a delay or failure to repair after
injury. In the blood system, HSC numbers increase with age
but HSC function declines (Morrison et al., 1996; Rossi et al.,
2005), leading to impaired stem cell engraftment potential and
skewed production of mature cell lineages by individual aged
HSCs (Dykstra et al., 2011). Stem cell function is similarly
impaired in the aged central nervous system (CNS), which
exhibits reduced neurogenesis at baseline (Molofsky et al.,
2006) and impaired remyelination activity after injury (Sim et al.,
2002), and in the skeletal muscle, where deficiencies in satellite
cell number and activation impede rapid repair of acutely
damaged muscle fibers (Brack et al., 2005; Collins et al., 2007;
Conboy et al., 2003, 2005). This inexorable decline in stem cell
function stimulated by advancing age likely contributes to the
progression of chronic diseases, particularly diseases that canspan several decades of life (such as multiple sclerosis and
some adult-onset forms of muscular dystrophy) and are there-
fore impacted by age-related deficits in tissue stem cells, even
if those deficits are unrelated to the disease-causing factors. In
this regard, recent studies in parabiotic mice have implicated
age-variant systemic factors, including soluble factors (Brack
et al., 2007; Conboy et al., 2005; Villeda et al., 2011) and circu-
lating hematopoietic cells (Ruckh et al., 2012), in modifying
the stem cell niche to promote or reverse the effects of aging
on stem and progenitor cell function. Such studies highlight
the dynamic nature of the stem cell niche, and the potential for
endocrine, as well as paracrine, control of tissue regenerative
function. These studies also point to discrete molecular entities,
including inactivated Notch signaling (Conboy et al., 2005) or
hyperactivated Wnt (Brack et al., 2007) or TGF-b (Carlson
et al., 2008) signaling in skeletal muscle, and excessive levels
of CCL11/eotaxin (Villeda et al., 2011) or ineffective activity of
recruited phagocytes (Ruckh et al., 2012) in the CNS, as niche-
derived targets for therapeutic intervention. Thus, niche-directed
strategies that revert the stem cell microenvironment to a more
‘‘youthful’’ state may be effective in reversing age-associated
stem cell defects and thereby restore robust regenerative
potential to aging tissues.
Interestingly, even young animals may experience remodeling
of stem cell niches that impacts tissue regenerative potential,
particularly if they are exposed to prolongedmetabolic perturba-
tions. Obese, insulin-resistant, and diabetic individuals exhibit
profound impairments in tissue repair, including ineffective heal-
ing of cutaneous wounds (Rafehi et al., 2011), poor regeneration
of injured skeletal muscle (Hu et al., 2010), and aberrant regula-
tion of immune and inflammatory cells (Mathis and Shoelson,
2011). As in aged animals, regenerative defects in the diabetic
state appear to be modulated at least in part by blood-borne
factors. Parabiotic experiments in a diabetic skin wounding
model, where diabetic animals (which normally show impaired
healing after skin wounding) were exposed to circulating factors
found in normoglycemic animals, showed an accelerated rate of
wound closure, enhanced angiogenesis, and an increased
recruitment of inflammatory cells thought to be important in
‘‘clean-up’’ of the wound site in diabetic mice following para-
biosis (Pietramaggiori et al., 2009). Likewise, recent data in the
hematopoietic system reported a significant impairment of
HSC mobilization in diabetic mice and patients (Ferraro et al.,
2011). Given that impaired angiogenesis and altered inflamma-
tory responses in many tissues are common manifestations of
advancing age and diabetes, it is possible that these may repre-
sent common mechanisms by which modifications in the stem
cell niche can suppress tissue regenerative function. Thus,
niche-based therapeutics that prevent or reverse these alter-
ations may be of broad benefit to the already large and ever-
increasing population of individuals diagnosed with diabetes or
metabolic syndrome.
In addition to aging and diabetes, endogenous targeting of the
stem cell nichemay also be desirable in situations of deregulated
cell growth leading to cancer. Several intriguing studies support
the existence of a specialized tumor microenvironment that
plays a particular role in encouraging tumor cell growth and
may promote the metastatic spread of malignant cancer stem
cells (reviewed in Raaijmakers, 2011; Sneddon and Werb,Cell Stem Cell 10, April 6, 2012 ª2012 Elsevier Inc. 365
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isolated from established tumors often exhibit alterations in their
gene expression profiles, including deregulation of secreted
factors that may promote cell growth or inhibit normal differenti-
ation. For example, stromal cells associated with human basal
cell carcinomas (BCCs) show enhanced expression of antago-
nists of the bone morphogenetic protein (BMP) pathway,
including Gremlin1 and Follistatin, when compared to normal
stroma, and ex vivo supplementation of cultures of BBC cells
with Gremlin1 inhibited BMP-stimulated tumor cell proliferation
(Sneddon et al., 2006). Similarly, the dependence of a number
of solid tumors, including pancreatic adenocarcinoma and colon
carcinoma, on activated Hedgehog (Hh) signaling has been
traced to a requirement for this pathway in the tumor mesen-
chyme, rather than in tumor cells themselves (Yauch et al.,
2008). In one particularly striking example of a ‘‘tumorigenic
niche,’’ conditional inactivation of the small RNA processing
enzyme Dicer specifically in mouse osteolineage cells induced
a modified niche that promoted myelodysplasia, leading ulti-
mately to the emergence of an acute myelogenous leukemia
that was independent of Dicer deletion in the hematopoietic
compartment (Raaijmakers et al., 2010). These data indicate
that gene disruption or deregulation in the niche can provide
a ‘‘fertile soil’’ for the growth of malignant clones, and may
underlie the emergence of some hematopoietic dysplasias. Tar-
geting such aberrant niches, particularly in the early stages of
disease, may be an effective strategy for reversing disease
course (Figure 2), a notion supported by the observation that
transplantation of dysplastic cells from the Dicer-deficient
microenvironment to a wild-type host failed to transfer disease
(Raaijmakers et al., 2010).
In a contrasting approach, recent studies suggest that target-
ing the niche to drive stem cell proliferation, rather than to inhibit
it, may also hold clinical utility. In particular, it has been sug-
gested that by altering the inflammatory tone of the stem cell
niche, via modulation of cytokines such as interferon-alpha
(IFN-a) and G-CSF, one might drive ‘‘dormant’’ HSCs or resting
leukemic stem cells into cycle and thereby enhance the effi-
ciency of chemotherapeutic ablation of tumor cells or of endog-
enous stem cells (which would likely enhance subsequent donor
cell engraftment) (Essers and Trumpp, 2010). Such effects might
also be accomplished by targeting nonmyelinating Schwann
cells in the bone marrow, which appear to be responsible for
maintaining HSC ‘‘hibernation’’ by activating latent TGF-b
(Yamazaki et al., 2011).
Such niche-directed strategies may prove themselves to be
equally relevant interventions in solid tumors as well. Studies in
a mouse model of neurofibroma indicate that haploinsufficiency
of the tumor suppressor NF1 in the nonneural cells of the tumor
microenvironment promotes tumor growth, in part by recruit-
ment of dysfunctional mast cells that produce critical tumor
growth factors (Yang et al., 2006; Zhu et al., 2002). Likewise,
cancer-associated fibroblasts (CAFs) found in association with
invasive breast cancers appear to support tumor initiation and
progression, in part by elaboration of the chemokine CXCL12
(also known as stromal derived factor-1, SDF-1), which acts
directly on breast cancer cells and also on endothelial progeni-
tors to stimulate tumor angiogenesis (Orimo et al., 2005). Finally,
modified niches may in some cases direct the formation of366 Cell Stem Cell 10, April 6, 2012 ª2012 Elsevier Inc.secondary tumors, producing factors that attract or retain meta-
static cells at particular locations (Kaplan et al., 2006; Wels et al.,
2008). In these situations, targeted strategies that ablate tumor-
supportive niche cells, disrupt homing to these niches, or alter
the ability of the niche to produce required growth factors or
‘‘metastatic beacons’’ may provide novel and effective strate-
gies for inhibiting tumor cell growth and malignant progression
(Jin et al., 2006; Lane et al., 2009; Raaijmakers, 2011).
Ex Vivo Models for Tissue Development and Disease:
Opening the ‘‘Black Box’’ of Degenerative Disease
Human degenerative diseases vary widely in their etiology,
pathology, and prognosis, and we know sadly little about the
causes and early events in the vast majority of these afflictions.
This knowledge gap relates in part to the fact that many degen-
erative diseases fail to manifest symptoms (and therefore gener-
ally lack diagnosis) until relatively late in the disease process,
when many of the disease-initiating and tissue destructive
events have already taken place. For example, in patients with
type 1 diabetes, a degenerative pathology evoked by autoim-
mune destruction of pancreatic beta cells, diagnosis typically
occurs only after the patient has lost 40%–90% of beta cell
mass, depending on age (Gale, 2002; Klinke, 2008). Likewise,
in Parkinson’s disease, it has been estimated that pigmented
neurons in the substantia nigra and striatal dopamine levels are
decreased by up to 50 and 80%, respectively, before the symp-
tomatic manifestation of their loss is detected (Fearnley and
Lees, 1991; Marsden, 1990; Ross et al., 2004). Unfortunately,
this complicated clinical situation forces a somewhat retrospec-
tive analysis of disease in human subjects, which generally is
insufficient to reveal the fundamental underlying mechanisms
that could be targeted early to prevent or reverse pathological
expression of disease phenotypes. In this regard, patient-
specific stem cells, which can undergo the same developmental
processes that give rise to disease pathology in vivo, provide
a unique opportunity to recapitulate disease processes in real
time, under experimental scrutiny and subject to intentional
manipulation, to discover exploitable vulnerabilities in the drivers
of pathology. The groundbreaking development of induced re-
programming technology (Park et al., 2008a, 2008b; Takahashi
et al., 2007; Takahashi and Yamanaka, 2006; Yu et al., 2007),
and the resulting possibility of generating disease-specific
induced pluripotent stem cells (iPSCs) from almost any human
patient (Park et al., 2008a), has made this possibility a reality
for many human disorders. Excitingly, studies that have charac-
terized disease-specific phenotypes of patient iPSCs and evalu-
ated the potential of these cells for drug discovery have for the
most part supported the utility of this approach (Brennand
et al., 2011; Kiskinis and Eggan, 2010; Liu et al., 2011; Zhang
et al., 2011). Yet, at the same time, such studies reinforce the
notion that highly reductionist approaches—which focus only
on the cell type that is lost or damaged in a given disease—
may overlook critical ‘‘niche effects’’ on disease progression.
An illustrative case in point, motor neurons generated from
mouse pluripotent stem cells expressing a mutant human gene
associated with familial cases of amyotrophic lateral sclerosis
(ALS, or ‘‘Lou Gehrig’s Disease,’’ a lethal neurodegenerative
disease caused by the death of motor neurons in the brain and
spinal cord; Boille´e et al., 2006) manifested a significantly greater
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carried the disease gene (Di Giorgio et al., 2007; Nagai et al.,
2007). These data implicated toxic mediators produced by glial
cells within the diseased neuronal niche as critical players in
motor neuron loss and disease progression, and further studies
using human pluripotent cell-derived motor neurons ultimately
identified prostaglandin D2 (PGD2) signaling as a critical medi-
ator of this toxic effect (Di Giorgio et al., 2008). Significantly,
inhibition of the PGD2 receptor provided substantial protection
to motor neurons cocultured with mutant glia, though this inter-
vention had no effect on motor neurons cultured with wild-type
glia (Di Giorgio et al., 2008). Thus, the discovery of this critical
disease-promoting mechanism in ALS relied upon an in vitro
system in which stem cells capable of producing the target cells
of a disease were exposed to the disease-modified niche cells
that signal their elimination.
Concluding Remarks
Stem cells hold tremendous potential for realizing the promise of
regenerative medicine, but these cells are not solo actors in the
drama of tissue maintenance and repair. As stem cells must
respond rapidly and appropriately to a multitude of extrinsic
signals, these cells are intricately connected with their surround-
ings and receive constant input from their niches, which direct
their subsequent behavior. Through better understanding of
the cellular players and molecular signals that constitute stem
cell niches under different physiological and pathological
conditions, we will develop more refined models of stem cell
responses and may ultimately be able to dictate their activities
to promote tissue regeneration. Likewise, by targeting dysfunc-
tional or deregulated niches, we may design new strategies to
combat stem cell loss, such as occurs in response to organismal
aging and degenerative disease, and to prevent or reversemalig-
nant transformation for the treatment of hematopoietic and non-
hematopoietic tumors. Success in these endeavors will require
a holistic view of stem cell regulation, exploiting new advances
in in vivo stem cell analysis and ex vivo modeling to uncover
novel entry points for niche-directed therapies.
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